Eligible patients must meet the following criteria to be enrolled in the study: 
1. Newly diagnosed, stage IV squamous cell lung cancer. This includes patients who present with disseminated metastases, and those with a malignant pleural or pericardial effusion (i.e., formerly stage IIIB in the 6th TNM staging system). 
2. Patients who have received prior adjuvant therapy for early-stage lung cancer are eligible if at least 12 months have elapsed from that treatment. 
3. Histologically confirmed squamous cell bronchogenic carcinoma. Patients whose tumors contain mixed non-small cell histologies are eligible, as long as squamous carcinoma is the predominant histology. Mixed tumors with small cell anaplastic elements are not eligible. Cytologic specimens obtained by brushings, washings, or needle aspiration of the defined lesion are acceptable. 
4. Patients with previous radiotherapy as definitive therapy for locally advanced non-small cell lung cancer are eligible, as long as the recurrence is outside the original radiation therapy port. Radiation therapy must have been completed >4 weeks prior to the initiation of study treatment. Patients who have received chemo/radiation for locally advanced NSCLC are not eligible. Patients who have received palliative radiation therapy for symptomatic metastases must have completed treatment >14 days prior the initiation of the study treatment. 
5. Presence of evaluable (measureable or non-measurable) disease. 
6. ECOG Performance Status of 0 or 1. 
7. Laboratory values as follows: 
Absolute neutrophil count (ANC) >1,500/microL and platelets >100,000/microL (≤72 hours prior to initial treatment). 
Hemoglobin >9 g/dL (Note: Patients may be transfused or receive erythropoietin to maintain or exceed this level). 
Bilirubin < ULN. 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the upper limit of normal if no liver involvement or ≤5 times the upper limit of normal with liver involvement. 
Creatinine <2.0 mg/dL, or creatinine clearance >40 mL/min (as calculated by the Cockcroft-Gault method. 
8. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and at least 6 months after the last dose of the study treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Sexually active men must agree to use a medically acceptable form of birth control during treatment and at least 6 months after the last dose. If a female partner becomes pregnant during the course of the study the treating physician should be informed immediately. 
9. >18 years of age. 
10. Ability to understand the nature of this study, give written informed consent, and comply with study requirements. 
11. Patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing. An exception to this is when the national/local regulations prohibits some of the key activities of this research like the export of samples to third countries, storage of coded samples or global gene expression profiling without a pre-specified list of target genes. If tissue is not available, a patient will still be eligible for enrollment into the study. 

NCT01082549_inc_T2
Mood
Newly diagnosed
NCT01082549_inc_T3
Temporal
Newly
NCT01082549_inc_T4
Qualifier
stage IV
NCT01082549_inc_T5
Measurement
stage
NCT01082549_inc_T6
Value
IV
NCT01082549_inc_T7
Condition
squamous cell lung cancer
NCT01082549_inc_T8
Condition
metastases
NCT01082549_inc_T9
Qualifier
disseminated
NCT01082549_inc_T10
Condition
pericardial effusion
NCT01082549_inc_T11
Condition
pleural effusion
NCT01082549_inc_T12
Qualifier
malignant
NCT01082549_inc_T13
Scope
pleural or pericardial effusion
NCT01082549_inc_T15
Measurement
6th TNM staging system
NCT01082549_inc_T16
Value
stage IIIB
NCT01082549_inc_T17
Scope
stage IIIB in the 6th TNM staging system
NCT01082549_inc_T14
Procedure
adjuvant therapy
NCT01082549_inc_T18
Condition
early-stage lung cancer
NCT01082549_inc_T19
Temporal
at least 12 months have elapsed from that treatment
NCT01082549_inc_T20
Reference_point
that treatment
NCT01082549_inc_T21
Procedure
treatment
NCT01082549_inc_T22
Scope
adjuvant therapy for early-stage lung cancer
NCT01082549_inc_T23
Condition
squamous cell bronchogenic carcinoma
NCT01082549_inc_T25
Procedure
Histologically
NCT01082549_inc_T26
Value
confirmed
NCT01082549_inc_T24
Condition
mixed non-small cell histologies
NCT01082549_inc_T27
Condition
squamous carcinoma
NCT01082549_inc_T28
Qualifier
predominant histology
NCT01082549_inc_T29
Observation
small cell anaplastic elements
NCT01082549_inc_T30
Negation
not
NCT01082549_inc_T31
Condition
Mixed tumors
NCT01082549_inc_T32
Qualifier
small cell anaplastic elements
NCT01082549_inc_T33
Procedure
radiotherapy
NCT01082549_inc_T34
Temporal
previous
NCT01082549_inc_T35
Qualifier
locally advanced
NCT01082549_inc_T36
Condition
non-small cell lung cancer
NCT01082549_inc_T38
Procedure
Radiation therapy
NCT01082549_inc_T39
Temporal
>4 weeks prior to the initiation of study treatment
NCT01082549_inc_T40
Reference_point
the initiation of study treatment
NCT01082549_inc_T41
Qualifier
locally advanced
NCT01082549_inc_T42
Condition
NSCLC
NCT01082549_inc_T43
Procedure
chemo
NCT01082549_inc_T44
Procedure
radiation
NCT01082549_inc_T45
Scope
chemo/radiation
NCT01082549_inc_T46
Negation
not
NCT01082549_inc_T47
Procedure
palliative radiation therapy
NCT01082549_inc_T48
Condition
symptomatic metastases
NCT01082549_inc_T49
Qualifier
symptomatic
NCT01082549_inc_T50
Temporal
>14 days prior the initiation of the study treatment
NCT01082549_inc_T51
Reference_point
the initiation of the study treatment
NCT01082549_inc_T53
Measurement
ECOG Performance Status
NCT01082549_inc_T54
Value
0 or 1
NCT01082549_inc_T55
Measurement
Absolute neutrophil count (ANC)
NCT01082549_inc_T56
Value
>1,500/microL
NCT01082549_inc_T57
Measurement
platelets
NCT01082549_inc_T58
Value
>100,000/microL
NCT01082549_inc_T59
Temporal
≤72 hours prior to initial treatment
NCT01082549_inc_T60
Reference_point
initial treatment
NCT01082549_inc_T61
Scope
Absolute neutrophil count (ANC) >1,500/microL and platelets >100,000/microL
NCT01082549_inc_T62
Measurement
Hemoglobin
NCT01082549_inc_T63
Value
>9 g/dL
NCT01082549_inc_T65
Measurement
Bilirubin
NCT01082549_inc_T66
Value
< ULN
NCT01082549_inc_T67
Measurement
Alanine aminotransferase (ALT)
NCT01082549_inc_T68
Measurement
aspartate aminotransferase (AST)
NCT01082549_inc_T69
Value
≤2.5 times the upper limit of normal
NCT01082549_inc_T70
Condition
liver involvement
NCT01082549_inc_T71
Negation
no
NCT01082549_inc_T73
Scope
no liver involvement
NCT01082549_inc_T74
Value
≤5 times the upper limit of normal
NCT01082549_inc_T75
Condition
liver involvement.
NCT01082549_inc_T76
Scope
≤2.5 times the upper limit of normal if no liver involvement or ≤5 times the upper limit of normal with liver involvement
NCT01082549_inc_T77
Measurement
Creatinine
NCT01082549_inc_T78
Value
<2.0 mg/dL
NCT01082549_inc_T79
Measurement
creatinine clearance
NCT01082549_inc_T80
Value
>40 mL/min
NCT01082549_inc_T81
Qualifier
Cockcroft-Gault method
NCT01082549_inc_T83
Value
>18 years
NCT01082549_inc_T84
Person
age